Stealth BioTherapeutics

In this holiday season, we cherish the connections we've made, the milestones we've achieved together, and the excitement of what is yet to come. May your holidays be filled with joy, and the New Year bring opportunities and continued progress. Happy Holidays and a Happy New Year from the entire Stealth team! 🎉

#DidYouKnow: We’re conducting a clinical study in dry age-related macular degeneration, a leading cause of blindness. Learn more about the ReNEW Phase 3 trial: https://lnkd.in/gt2CxjyW    #dryAMD 

#BarthSyndrome is a #RareDisease that affects the muscles, and can lead to serious heart problems, debilitating fatigue, lack of appetite, growth delays, and more. It impacts all aspects of life. Over the past decade, we have had the tremendous privilege to meet many individuals living with Barth syndrome and their families and loved ones. To truly understand this condition, it’s important to hear directly from patients and families. Learn more by watching Abe’s story in the video below. https://lnkd.in/g5E_HiAH

Stealth recently had the privilege of presenting at the International Congress for Ataxia Research (ICAR), where we shared pre-clinical findings from studying our investigational pipeline-compound in aggressive cardiac models of Friedreich’s ataxia. We are encouraged by the findings and look forward to continuing the development of this mitochondria-targeting compound. #ICAR2024 #FriedreichsAtaxia

Stealth is excited to share a recent publication in the Orphanet Journal of Rare Diseases on our SPIMM-301 study subgroup analysis manuscript. Access the full article here: https://bit.ly/4i2wjuh

November is National #FamilyCaregiversMonth. Stealth would like to thank and honor the selfless individuals who provide essential care and support to their loved ones. National Family Caregivers Month was established to recognize the significant contributions of family caregivers and to raise awareness about the challenges they face.     Here are some helpful resources from Caregiver Action Network to support caregivers in juggling their many responsibilities while working to take care of their own wellbeing: https://lnkd.in/gXRwxhKr #FamilyCaregivers #SupportCaregivers #NFCMonth

We’re right around the corner from the world's largest conference of ataxia researchers! Happening at #ICAR2024 in London, England, Stealth will be presenting new data on pre-clinical models in Friedreich’s ataxia (FA). Looking forward to an exciting conference!  https://lnkd.in/eemV2Q4E

Attending CNS Summit 2024? Be sure to tune in to the Medicines for Mito spotlight session to hear from Stealth CEO, Reenie McCarthy, alongside fellow life science leaders as they discuss the impact of mitochondrial disease and the potential of mitochondria-targeted therapeutics. #CNSummit2024 https://lnkd.in/g4wrh-gQ

We’re pleased to share that the results of ReCLAIM-2, our Phase 2 study in dry age-related macular degeneration (AMD) with non-central geographic atrophy, were recently published in Ophthalmology Science, a peer-reviewed journal of the American Academy of Ophthalmology. Key learnings from ReCLAIM-2 informed our Phase 3 program, including the ongoing ReNEW study which is currently enrolling participants. Read the publication here: https://lnkd.in/eU-XNgqy 

Congrats to Dr. Hilary Vernon for being named a 2024 RARE Champion of Hope! Thank you for your continued work and championing in the rare and ultra-rare disease communities!